Samrotamab
Based on 1 Customer Validation
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 96.00%
- No. CAS: 2052591-32-7
- Peso molecular:145.92 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Human IgG1 kappa
Human
LRRC15
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Samrotamab on AHC2 biosensor, can bind LRRC15 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78172) with an affinity constant of 5.759E-10 M as determined in BLI assay.
Chemical Information
-
No. CAS 2052591-32-7
-
Appearance Liquid
-
Peso molecular 145.92 kDa
-
Color Colorless to light yellow
-
SMILES
[Samrotamab]
-
Synonyms
PR-1498487
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)